Human use of avian-human reassortants as vaccines for influenza A virus
US4552758A · kind A · utility
46Cited by
4References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 20, 1983 |
| Grant date | Nov 12, 1985 |
| Priority date | — |
| Expiry date | Dec 20, 2003 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/16161
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of producing a live attenuated vaccine useful in humans which comprises producing an influenza A reassortant virus by gene exchange between an avian influenza virus parent and a human influenza virus parent and then excluding the internal genes (that code for non-surface viral proteins) of the human influenza virus parent from the reassortant by temperature selection and excluding the surface antigen genes of the avian influenza A virus parent by antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.